Multi-center Performance Evaluations of Tacrolimus and Cyclosporine Electrochemiluminescence Immunoassays in the Asia-Pacific Region
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: The immunosuppressant drugs (ISDs), tacrolimus and cyclosporine, are vital for solid organ transplant patients to prevent rejection. However, toxicity is a concern, and absorption is highly variable across patients; therefore, ISD levels need to be precisely monitored. In the Asia-Pacific (APAC) region, tacrolimus and cyclosporine concentrations are typically measured using immunoassays. The objective of this study was to assess the analytical performance of Roche Elecsystacrolimus and cyclosporinee electrochemiluminescence immunoassays (ECLIAs). Methods: This evaluation was performed in seven centers across China, South Korea, and Malaysia. Imprecision (repeatability and reproducibility), assay accuracy, and lot-to-lot reagent variability were tested. The Elecsys ECLIAs were compared with commercially available immunoassays (Architect, Dimension, and Viva-E systems) using whole blood samples from patients with various transplant types (kidney, liver, heart, and bone marrow). Results: Coefficients of variation for repeatability and reproducibility were ≤5.4% and ≤12.4%, respectively, for the tacrolimus ECLIA, and ≤5.1% and ≤7.3%, respectively, for the cyclosporine ECLIA. Method comparisons of the tacrolimus ECLIA with Architect, Dimension, and Viva-E systems yielded slope values of 1.01, 1.14, and 0.897, respectively. The cyclosporine ECLIA showed even closer agreements with the Architect, Dimension, and Viva-E systems (slope values of 1.04, 1.04, and 1.09, respectively). No major differences were observed among the different transplant types. Conclusions: The tacrolimus and cyclosporine ECLIAs demonstrated excellent precision and close agreement with other immunoassays tested. These results show that both assays are suitable for ISD monitoring in an APAC population across a range of different transplant types.
Abstract
Background: The immunosuppressant drugs (ISDs), tacrolimus and cyclosporine, are vital for solid organ transplant patients to prevent rejection. However, toxicity is a concern, and absorption is highly variable across patients; therefore, ISD levels need to be precisely monitored. In the Asia-Pacific (APAC) region, tacrolimus and cyclosporine concentrations are typically measured using immunoassays. The objective of this study was to assess the analytical performance of Roche Elecsystacrolimus and cyclosporinee electrochemiluminescence immunoassays (ECLIAs). Methods: This evaluation was performed in seven centers across China, South Korea, and Malaysia. Imprecision (repeatability and reproducibility), assay accuracy, and lot-to-lot reagent variability were tested. The Elecsys ECLIAs were compared with commercially available immunoassays (Architect, Dimension, and Viva-E systems) using whole blood samples from patients with various transplant types (kidney, liver, heart, and bone marrow). Results: Coefficients of variation for repeatability and reproducibility were ≤5.4% and ≤12.4%, respectively, for the tacrolimus ECLIA, and ≤5.1% and ≤7.3%, respectively, for the cyclosporine ECLIA. Method comparisons of the tacrolimus ECLIA with Architect, Dimension, and Viva-E systems yielded slope values of 1.01, 1.14, and 0.897, respectively. The cyclosporine ECLIA showed even closer agreements with the Architect, Dimension, and Viva-E systems (slope values of 1.04, 1.04, and 1.09, respectively). No major differences were observed among the different transplant types. Conclusions: The tacrolimus and cyclosporine ECLIAs demonstrated excellent precision and close agreement with other immunoassays tested. These results show that both assays are suitable for ISD monitoring in an APAC population across a range of different transplant types.
참고문헌 (40)
- Khurana A, "Pathology of solid organ transplantation" (2011), Springer
- Haddad EM, "Cyclosporin versus tacrolimus for liver transplanted patients", Cochrane Database Syst Rev, 4 (2006)
- Webster A, "Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients", Cochrane Database Syst Rev, 4 (2005)
- Khan S, "Immunosuppressive drug therapy--biopharmaceutical challenges and remedies", Expert Opin Drug Deliv, 12, pp.1333~1349 (2015)[DOI]
- Holt DW, "International Federation of Clinical Chemistry", International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring, 2002, pp.24, 59~67
- 강주섭, "Overview of Therapeutic Drug Monitoring", The Korean Journal of Internal Medicine, 24(1), pp.1~10 (2009), 대한내과학회
- Shipkova M, "Multi-center analytical evaluation of a novel automated tacrolimus immunoassay", Clin Biochem, 47, pp.1069~1077 (2014)[DOI]
- Vogeser M, "Multicenter analytical evaluation of the automated electrochemiluminescence immunoassay for cyclosporine", Ther Drug Monit, 36, pp.640~650 (2014)[DOI]
- Xie F, "An update on the role of intestinal cytochrome P450 enzymes in drug disposition", Acta Pharm Sin B, 6, pp.374~383 (2016)[DOI]
- Zhou HH, "Ethnic differences in drug metabolism", Clin Chem Lab Med, 38, pp.899~903 (2000)
- Jovanovik M, "Inferring cuisine--drug interactions using the linked data approach", Sci Rep, 5, pp.9346~ (2015)[DOI]
- Seger C, "Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee", Ther Drug Monit, 38, pp.170~189 (2016)[DOI]
- Wallemacq P, "Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference", Ther Drug Monit, 31, pp.139~152 (2009)[DOI]
- Volosov A, "Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography--tandem mass-spectrometry", Clin Biochem, 34, pp.285~290 (2001)[DOI]
- Wu AH, "Implementation of liquid chromatography", mass spectrometry into the clinical laboratory, 2013, pp.420, 4~10
- Gounden V, "Tacrolimus measurement: building a better immunoassay", Clin Chem, 60, pp.575~576 (2014)[DOI]
- "Cyclosporine: method sheet"[URL]
- "Tacrolimus: method sheet"[URL]
- "Architect system: Cyclosporine" (2010)[URL]
- "Architect system: Tacrolimus" (2009)[URL]
- "Dimension Cyclosporine (CSA) and Cyclosporine Extended Range (CSAE) Assays" (2008)[URL]
- "<TEX>$Emit^{(R)}$</TEX> 2000 Tacrolimus (TACR) Assay" (2008)[URL]
- "<TEX>$Emit^{(R)}$</TEX> 2000 Cyclosporine A (CsA) Assay" (2008)[URL]
- "Royal College of Pathologists of Australasia"[URL]
- Clinical and Laboratory Standards Institute, "Evaluation of precision of quantitative measurement methods: approved guideline - third edition: EP05-A3", Clinical and Laboratory Standards Institute, ~ (2014)
- Clinical and Laboratory Standards Institute, "Measurement procedure comparison and bias estimation using patient samples; approved guideline - third edition: EP09-A3", Clinical and Laboratory Standards Institute, ~ (2013)
- Serdarevic N, "Comparison of Architect I 2000 for determination of cyclosporine with AxSYM", Acta Inform Med, 20, pp.214~217 (2012)[DOI]
- Wallemacq P, "Multisite analytical evaluation of the Abbott ARCHITECT cyclosporine assay", Ther Drug Monit, 32, pp.145~151 (2010)
- Chavan P, "Cyclosporine drug levels: comparison of the Architect 1000i with the Siemens Dimension RXL system", J Lab Physicians, 7, pp.137~ (2015)[DOI]
- Amann S, "Evaluation of 2 immunoassays for monitoring low blood levels of tacrolimus", Ther Drug Monit, 31, pp.273~276 (2009)[DOI]
- Jorga A, "Therapeutic drug monitoring of cyclosporine", Transplant Proc, 36, pp.396S~403S (2004)[DOI]
- Vuceljic M, "Comparison of two commercial cyclosporin assays", J Med Biochem, 26, pp.33~37 (2007)
- Ko DH, "Performance evaluation of a restored Dimension TACR assay: an automated platform for measuring the whole blood tacrolimus concentration", Clin Lab, 62, pp.7~12 (2016)
- 정혜선, "약물분석장비 Viva-E의 평가", Annals of Laboratory Medicine, 27(5), pp.330~337 (2007), 대한진단검사의학회
- Holt DW, "Long-term evaluation of analytical methods used in sirolimus therapeutic drug monitoring", Clin Transplant, 28, pp.243~251 (2014)[DOI]
- Morelle J, "Clinically unexpected cyclosporine levels using the ACMIA method on the RXL dimension analyser", Nephrol Dial Transplant, 26, pp.1428~1431 (2011)[DOI]
- Hermida J, "Falsely increased blood tacrolimus concentrations using the ACMIA assay due to circulating endogenous antibodies in a liver transplant recipient: a tentative approach to obtaining reliable results", Ther Drug Monit, 31, pp.269~272 (2009)[DOI]
- Christians U, "Impact of laboratory practices on interlaboratory variability in therapeutic drug monitoring of immunosuppressive drugs", Ther Drug Monit, 37, pp.718~724 (2015)[DOI]
- Yatscoff RW, "The clinical significance of cyclosporine metabolites", Clin Biochem, 24, pp.23~35 (1991)[DOI]
- Christians U, "Cyclosporin metabolism in transplant patients", Pharmacol Ther, 57, pp.291~345 (1993)[DOI]